ADC Development Services Targeting BCMA

The restricted expression pattern of B-cell maturation antigen (BCMA) makes it a very selective antigen to be targeted by novel immune-based strategies for the treatment of multiple myeloma (MM). With more than 10 years of experience in antibody  discovery and bio-conjugation, Creative Biolabs is a leading expert for the conjugation of highly active molecules to monoclonal antibodies (mAbs) for the development and manufacture of ADCs. As a well-recognized leader in ADC preparation, Creative Biolabs provides novel anti-BCMA ADC development services to help our worldwide clients. Catalog Anti-BCMA ADC Products are also optional for our worldwide clients.

Introduction of BCMA

BCMA, also known as TNFRSF17, is a type III transmembrane glycoprotein and non-tyrosine kinase receptor which belongs to the tumor necrosis factor receptor (TNFR) superfamily. BCMA contains 184 amino acids and is a natural substrate for γ-secretase, a multi-subunit protease complex, resulting in its decreased level on the cell membrane and formation of soluble BCMA (sBCMA). BCMA is ubiquitously expressed on MM cells and its serum levels correlate with response to therapy and overall survival in patients with MM. The development of novel agents targeting BCMA is improving fast. Currently, there are multiple BCMA-based treatment modalities including ADC, bispecific T-cell engager (BiTE), chimeric antigen receptor (CAR) T cells (CAR T), bispecific molecule, and bi/trispecific Abs.

Fig.1 Multiple promising BCMA-targeting immunotherapies in MM. (Tai, 2015)

Anti-BCMA ADC in Multiple Myeloma

ADC is one of the fastest growing class of anti-MM therapeutics. Take GSK285791 as an example, it is a humanized IgG1 mAb with high affinity to BCMA (Kd of ~0.5 nM), which uses non-cleavable linker, maleimidocaproyl (mc), and a new class of antimitotic agents, monomethyl auristatin F, as payload. This ADC is characterized by high stability and high antitumor potency, with low by-stander toxicity. Upon binding to BCMA on the cell surface, GSK2857916 is rapidly internalized and the cytotoxic moiety is released, leading to direct cell death. GSK2857916 was evaluated in a phase 1 study of patients with relapsed and refractory multiple myeloma (RRMM). GSK2857916 monotherapy has demonstrated a 60% response rate and a median progression-free survival of 7.9 months in a group of hard to treat and heavily pretreated RRMM. It has recently been awarded Breakthrough Therapy designation from FDA and received PRIME designation from the European Medicines Agency (EMA).

What Can We Do for You?

Creative Biolabs provides ADC development and manufacturing services with high-quality antibodies, linkers and conjugation strategy. Creative Biolabs has years of experience in the production and testing of mAbs, giving us the ability to provide complete testing for the bulk mAb and ADC products. We offer a whole suite of technology platform and services needed for ADCs, including:

• ADC Antibody Screening
• Antibody Design and Conjugation
• DrugLnk™ Custom Synthesis
• ADC in vitro Analysis
• ADC in vivo Analysis
• ChimtoximAb Platform
• Quenchbody Development
• ADC Manufacturing

If you are interested in our anti-BCMA ADC development services, please feel free to contact us for more information.

Reference

1. Tai, Y. T.; Anderson, K. C. Targeting B-cell maturation antigen in multiple myeloma. Immunotherapy. 2015, 7(11): 1187-1199.